亚宝药业: 亚宝药业集团股份有限公司关于取得药品注册证书的公告

Core Viewpoint - Company has received the drug registration certificate for Isopropylphenazone injection from the National Medical Products Administration, enhancing its product portfolio and market competitiveness [1][2]. Group 1: Drug Registration Certificate - The drug registration certificate for Isopropylphenazone injection was approved and issued by the National Medical Products Administration, with certificate number 2025S00738 [1]. - The product is indicated for acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1]. Group 2: Market and Sales Data - The Isopropylphenazone injection was developed by Laboratoire L.lafon and was approved for sale in France in 1993, with Teva Sante as the current license holder under the brand name Spasfon® [1]. - According to data from Minet, the sales amount of Isopropylphenazone injection in China for 2023 is approximately 1.387 billion RMB [1]. Group 3: Competitive Landscape - As of the announcement date, there are three other companies in China that have obtained registration approval for Isopropylphenazone injection [2]. - The acquisition of the registration certificate is expected to improve the company's product competitiveness in the market [2].